Blood-to-Brain Glucose Transport, Cerebral Glucose Metabolism, and Cerebral Blood Flow Are Not Increased After Hypoglycemia

Scott A. Segel,[1,3,4] Carmine G. Fanelli,[1,3,4] Carmen S. Dence,[2] Joanne Markham,[2] Tom O. Videen,[2] Deanna S. Paramore,[1,3,4] William J. Powers,[2,5] and Philip E. Cryer[1,3,4]

Recent antecedent hypoglycemia has been found to shift glycemic thresholds for autonomic (including adrenomedullary epinephrine), symptomatic, and other responses to subsequent hypoglycemia to lower plasma glucose concentrations. This change in threshold is the basis of the clinical syndromes of hypoglycemia unawareness and, in part, defective glucose counterregulation and the unifying concept of hypoglycemia-associated autonomic failure in type 1 diabetes. We tested in healthy young adults the hypothesis that recent antecedent hypoglycemia increases blood-to-brain glucose transport, a plausible mechanism of this phenomenon. Eight subjects were studied after euglycemia, and nine were studied after ~24 h of interprandial hypoglycemia (~55 mg/dl, ~3.0 mmol/l). The latter were shown to have reduced plasma epinephrine ($P = 0.009$), neurogenic symptoms ($P = 0.009$), and other responses to subsequent hypoglycemia. Global bihemispheric blood-to-brain glucose transport and cerebral glucose metabolism were calculated from rate constants derived from blood and brain time-activity curves—the latter determined by positron emission tomography (PET)—after intravenous injection of [1-^{11}C]glucose at clamped plasma glucose concentrations of 65 mg/dl (3.6 mmol/l). For these calculations, a model was used that includes a fourth rate constant to account for egress of [^{11}C] metabolites. Cerebral blood flow was measured with intravenous [^{15}O]water using PET. After euglycemia and after hypoglycemia, rates of blood-to-brain glucose transport (24.6 ± 2.3 and 22.4 ± 2.4 μmol · 100 g^{-1} · min^{-1}, respectively), cerebral glucose metabolism (16.8 ± 0.9 and 15.9 ± 0.9 μmol · 100 g^{-1} · min^{-1}, respectively) and cerebral blood flow (56.8 ± 3.9 and 53.3 ± 4.4 ml · 100 g^{-1} · min^{-1}, respectively) were virtually identical. These data do not support the hypothesis that recent antecedent hypoglycemia increases blood-to-brain glucose transport during subsequent hypoglycemia. They do not exclude regional increments in blood-to-brain glucose transport. Alternatively, the fundamental alteration might lie beyond the blood-brain barrier. *Diabetes* 50:1911–1917, 2001

Iatrogenic hypoglycemia is the limiting factor in the glycemic management of diabetes, both conceptually and in practice (1,2). It causes recurrent and sometimes permanent physical morbidity, recurrent or persistent psychosocial morbidity, and occasionally death. It precludes true glycemic control in most patients with type 1 diabetes (3) and many of those with advanced type 2 diabetes (4). Because of the barrier of iatrogenic hypoglycemia, long-term complications of diabetes often develop or progress despite aggressive attempts at glycemic control, albeit at lower rates than during less aggressive therapy (3,4).

At least in type 1 diabetes, iatrogenic hypoglycemia is the result of the interplay of relative or absolute therapeutic insulin excess and compromised physiological and behavioral defenses against developing hypoglycemia (1,2). In established (i.e., C-peptide–negative) type 1 diabetes, circulating insulin levels are unregulated and do not decline as plasma glucose levels decline; the first defense against hypoglycemia is lost. The second defense against developing hypoglycemia, an increase in glucagon secretion in response to falling plasma glucose levels, is also lost in established type 1 diabetes (5,6). Thus, patients with established type 1 diabetes are largely dependent on the third defense against developing hypoglycemia: increased epinephrine secretion. However, that too is often attenuated in type 1 diabetes (6). Those patients with combined deficiencies of their glucagon and epinephrine responses to falling plasma glucose levels have the clinical syndrome of defective glucose counterregulation. Their risk of severe iatrogenic hypoglycemia is ≥25-fold higher than that of patients with absent glucagon but normal epinephrine responses (7,8). Those with reduced epinephrine (i.e., reduced sympathochromaffin) responses also have the clinical syndrome of hypoglycemia unawareness: the loss of warning, largely neurogenic (autonomic) symptoms of developing hypoglycemia, which also often results in episodes of severe hypoglycemia (9).

The concept of hypoglycemia-associated autonomic failure in type 1 diabetes (10–14) posits that because it reduces the autonomic (including adrenomedullary epinephrine as well as sympathetic neural norepinephrine and acetylcholine) and symptomatic responses to a given level of subsequent hypoglycemia, recent antecedent iatrogenic hypoglycemia causes hypoglycemia unawareness.

In addition, because it reduces epinephrine responses in the setting of absent glucagon responses, recent antecedent iatrogenic hypoglycemia also causes defective glucose counterregulation. Perhaps the most compelling support for this concept is the finding in three independent laboratories (14–16) that as little as 2–3 weeks of scrupulous avoidance of iatrogenic hypoglycemia typically reverses hypoglycemia unawareness completely and improves the reduced epinephrine component of defective glucose counterregulation.

The mechanism of hypoglycemia-associated autonomic failure in type 1 diabetes is unknown. The brain glucose transport hypothesis, which posits that recent antecedent hypoglycemia increases blood-to-brain glucose transport during subsequent hypoglycemia, is based on data in rodents and humans. There is substantial evidence that 3–5 days (17–19) or 14 days (20) of hypoglycemia causes increased brain glucose uptake and increased brain microvascular (i.e., blood-brain barrier) GLUT1 mRNA and protein in rats. Boyle et al. (21) reported that 56 h of interprandial hypoglycemia increased brain glucose uptake (determined with the Kety-Schmidt technique) during hypoglycemia in healthy humans and that brain glucose uptake was preserved during hypoglycemia in patients with well-controlled, and frequently hypoglycemic, type 1 diabetes (22). These data suggest that antecedent hypoglycemia causes increased blood-to-brain glucose transport at a given level of subsequent hypoglycemia, a plausible mechanism of hypoglycemia-associated autonomic failure in type 1 diabetes. Accordingly, we measured blood-to-brain glucose transport, along with cerebral glucose metabolism and cerebral blood flow, with positron emission tomography (PET) (23,24) during mild hypoglycemia (65 mg/dl, 3.6 mmol/l) in healthy human subjects after euglycemia and after ~24 h of interprandial hypoglycemia (~55 mg/dl, ~3.0 mmol/l) to test the hypothesis that recent antecedent hypoglycemia causes increased blood-to-brain glucose transport.

RESEARCH DESIGN AND METHODS

A total of 17 healthy young adults gave their informed consent to participate in this study, which was approved by the Washington University Human Studies Committee and conducted at the Washington University General Clinical Research Center (GCRC). Nine subjects (four women, five men) were studied after ~24 h of hypoglycemia (see below). Their age (means ± SD) was 24.9 ± 5.0 years. Eight subjects were studied after ambient euglycemia (three women, five men). Their mean age was 26.6 ± 5.5 years.

Experimental design. Subjects to be studied after hypoglycemia were admitted to the GCRC after an overnight fast early on the morning of day 1. Intravenous lines were inserted into an antecubital vein (for subsequent insulin and glucose infusions) and a contralateral hand vein (with that hand kept in an ~55°C plexiglas box for arterialized venous sampling). Observations (see below) were made at ambient plasma glucose concentrations (~90 mg/dl, ~5.0 mmol/l) from 0600–0700. Then, hyperinsulinemic (2.0 mU · kg^{-1} · min^{-1}, 12.0 pmol · kg^{-1} · min^{-1}) stepped hypoglycemic clamps (25) were performed, and 20% dextrose was infused at variable rates, based on plasma glucose measurements every 5 min, to clamp plasma glucose concentrations at nominal levels of 85 mg/dl (4.7 mmol/l), 75 mg/dl (4.2 mmol/l), 65 mg/dl (3.6 mmol/l), and 55 mg/dl (3.0 mmol/l) in hourly steps. Then, insulin infusions were adjusted to hold plasma glucose concentrations at ~55 mg/dl (~3.0 mmol/l) between meals (lunch, dinner, and snack) until around 0630 on day 2, when glucose levels were raised, and the hyperinsulinemic stepped hypoglycemic clamps were repeated. After the final hypoglycemic step, at 55 mg/dl (3.0 mmol/l), plasma glucose concentrations were clamped at 65 mg/dl (3.6 mg/dl mmol/l), at around 1100, and maintained thereafter. At that point, an arterial sampling line was inserted, and the initial PET studies (see below) were performed. [1-^{11}C]glucose was injected at around 1300.

Subjects to be studied after euglycemia reported to the GCRC after an overnight fast on the morning of the PET studies. Hyperinsulinemic (2.0 mU · kg^{-1} · min^{-1}, 12.0 pmol · kg^{-1} · min^{-1}) mildly hypoglycemic (65 mg/dl, 3.6 mmol/l) clamps were established by 1100, and PET studies (see below) were performed as in the subjects studied after hypoglycemia.

Observations and analytical methods. Arterialized venous plasma glucose concentrations were measured with a glucose oxidase method (Beckman Glucose Analyzer 2; Beckman Instruments, Brea, CA). Arterialized venous samples for other analytes were obtained at 30-min intervals before and during the glucose clamps. Plasma insulin (26), glucagon (27), pancreatic polypeptide (28), growth hormone (29) and cortisol (30) were measured with radioimmunoassay. Plasma epinephrine and norepinephrine were measured with a single isotope derivative (radioenzymatic) method (31). Serum nonesterified fatty acids (32) and blood β-hydroxybutyrate (33), lactate (34), and alanine (35) were measured with enzymatic methods. Symptoms of hypoglycemia were quantitated at 15-min intervals during the glucose clamps by asking the subjects to score (0 = none to 6 = severe) 12 different symptoms, comprised of 6 neurogenic and 6 neuroglycopenic symptoms. The neurogenic symptoms (adrenergic: heart pounding, shaky/tremulous, and nervous/anxious; cholinergic: sweaty, hungry, and tingling) and neuroglycopenic symptoms (difficulty thinking/confused, tired/drowsy, weak, warm, faint, and dizzy) were based on our previously published data (36). Heart rates and blood pressures were recorded automatically (Propaq Encore; Protocol Systems, Beverton, OR) at 15-min intervals, and the ECG was monitored throughout the hypoglycemic clamps.

PET methods. Global bihemispheric rates of blood-to-brain glucose transport and cerebral glucose metabolism were calculated from rate constants derived from blood and brain time-activity curves (the latter determined by PET) after intravenous injection of [1-^{11}C]glucose using a model that includes a fourth rate constant to account for egress of [^{11}C]metabolites (23,24). Bihemispheric cerebral blood volume was measured with inhaled [^{15}O]carbon monoxide (37,38), and bihemispheric cerebral blood flow was measured with intravenously injected [^{15}O]water (37,39), also using PET. These methods have been previously described in detail (23,24,37–39). The [1-^{11}C]glucose PET method has been validated in macaques, in which is was shown that net brain glucose extraction measured with the PET method was correlated with that determined by arteriovenous differences; it was also shown that blood-to-brain glucose transport was related to arterial glucose extraction using appropriate Michaelis-Menten kinetics (23). This method was also applied in an earlier study in humans (24). More recently, we have shown that the rates of blood-to-brain glucose transport and cerebral glucose metabolism determined with the PET method are unaffected by circulating radiolabeled nonglucose metabolites (40). Blood-to-brain glucose transport determined with this method has been shown to vary as a function of the plasma glucose concentration (23,41).

Statistical methods. Data in this manuscript are reported as the means ± SE, except where SD is specified. Data from the hyperinsulinemic stepped hypoglycemic clamps were analyzed by repeated-measures analysis of variance. Those from the PET studies were analyzed by t test. P values < 0.050 were considered to indicate statistically significant differences.

RESULTS

Effects of antecedent hypoglycemia. Hourly plasma glucose concentrations (mean ± SE), including those after lunch, dinner, and a snack, were 64 ± 1 mg/dl (3.6 ± 0.1 mmol/l) between the stepped hypoglycemic clamps on day 1 and the clamps on day 2 in the subjects studied after hypoglycemia (Figs. 1-4, Table 1). During the hyperinsulinemic stepped hypoglycemic clamps, plasma insulin concentrations were raised comparably, and target plasma glucose concentrations (85, 75, 65, and 55 mg/dl; 4.7, 4.2, 3.6, and 3.0 mmol/l, respectively) were achieved on days 1 and 2 (Fig. 1). Compared with the responses on day 1, plasma epinephrine responses to hypoglycemia were reduced ($P = 0.009$) on day 2 after interval hypoglycemia; plasma norepinephrine responses were not reduced significantly ($P = 0.290$) (Fig. 2). Compared with the responses on day 1, neurogenic (autonomic) symptom score responses to hypoglycemia were reduced ($P = 0.009$) on day 2 after interval hypoglycemia; neuroglycopenic symptom score responses were not reduced significantly ($P = 0.130$)

FIG. 1. Mean ± SE plasma values for insulin (*A*) and glucose (*B*) concentrations before and during hyperinsulinemic stepped hypoglycemic clamps before (day 1, ■) and after (day 2, □) ~24 h of hypoglycemia (55 mg/dl, 3.0 mmol/l) in nine subjects who underwent PET studies after hypoglycemia.

FIG. 2. Mean ± SE values for plasma epinephrine (*A*) and norepinephrine (*B*) concentrations before and during hyperinsulinemic stepped hypoglycemic clamps before (day 1, ■) and after (day 2, □) ~24 h of hypoglycemia (55 mg/dl, 3.0 mmol/l) in nine subjects who underwent PET studies after hypoglycemia.

(Fig. 3). Compared with the responses on day 1, plasma glucagon responses to hypoglycemia were reduced ($P = 0.031$) on day 2 after interval hypoglycemia; plasma pancreatic polypeptide responses were not reduced significantly ($P = 0.134$) (Fig. 4). Compared with the responses on day 1, plasma growth hormone responses to hypoglycemia were reduced ($P = 0.001$) on day 2 after interval hypoglycemia; plasma cortisol responses were not reduced significantly ($P = 0.087$) (Table 1). Serum nonesterified fatty acid levels and blood β-hydroxybutyrate and alanine levels were similar on days 1 and 2 (Table 1); blood lactate responses were reduced on day 2 (Table 1).

PET studies after hypoglycemia and after euglycemia. During the PET studies, plasma arterial glucose concentrations were clamped at comparable mildly hypoglycemic levels of 66 ± 1 mg/dl (3.7 ± 0.1 mmol/l) in the nine subjects studied after hypoglycemia and 64 ± 0 mg/dl (3.6 ± 0.0 mmol/l) in the eight subjects studied after

euglycemia (Table 2, Fig. 5). The circulating levels of neuroendocrine parameters were lower, or tended to be lower, in the subjects studied after hypoglycemia compared with those studied after euglycemia (Table 2).

Global bihemispheric rates of blood-to-brain glucose transport (24.6 ± 2.3 vs. 22.4 ± 2.4 μmol · 100 g^{-1} · min^{-1} after euglycemia and after hypoglycemia, respectively), cerebral glucose metabolism (16.8 ± 0.9 vs. 15.9 ± 0.9 μmol · 100 g^{-1} · min^{-1} after euglycemia and after hypoglycemia, respectively), and cerebral blood flow (56.8 ± 3.9 vs. 53.3 ± 4.4 ml · 100 g^{-1} · min^{-1} after euglycemia and after hypoglycemia, respectively) were virtually identical under the two study conditions (Fig. 5). In addition, cerebral blood volumes (3.63 ± 0.11 vs. 3.25 ± 0.14 ml/100 g after euglycemia and after hypoglycemia, respectively) were similar. Based on calculations of the confidence intervals for the differences between the groups, the proba-

TABLE 1
Plasma growth hormone, cortisol, serum nonesterified fatty acids, blood β-hydroxybutyrate, lactate, and alanine concentrations before and during hyperinsulinemic stepped hypoglycemic clamps before (Day 1) and after (Day 2) approximately 24 h of hypoglycemia (55 mg/dl, 3.0 mmol/l) in nine subjects who underwent PET studies after hypoglycemia

	Nominal glucose (mg/dl)					
	~90	85	75	65	55	*P*
Growth hormone (ng/ml)*						
Day 1	1.3 ± 0.7	1.5 ± 1.0	2.1 ± 1.5	7.7 ± 2.1	18.2 ± 2.4	0.001
Day 2	1.1 ± 0.4	3.5 ± 2.4	5.1 ± 2.4	2.6 ± 1.3	8.4 ± 2.8	
Cortisol (μg/dl)†						
Day 1	11.5 ± 1.6	10.3 ± 1.7	8.9 ± 1.1	12.5 ± 1.6	17.1 ± 1.8	0.087
Day 2	13.4 ± 1.8	9.8 ± 1.7	12.4 ± 3.1	9.8 ± 2.0	17.4 ± 3.6	
Nonesterified fatty acids (μmol/l)						
Day 1	381 ± 76	104 ± 26	79 ± 14	79 ± 20	66 ± 22	0.592
Day 2	307 ± 84	74 ± 8	54 ± 7	48 ± 10	45 ± 10	
β-Hydroxybutyrate (μmol/l)						
Day 1	145 ± 37	64 ± 24	106 ± 38	66 ± 24	66 ± 17	0.927
Day 2	111 ± 22	86 ± 22	64 ± 18	84 ± 28	68 ± 19	
Lactate (μmol/l)						
Day 1	1045 ± 129	1451 ± 163	1349 ± 95	1308 ± 81	1824 ± 231	0.001
Day 2	963 ± 115	1024 ± 68	839 ± 90	753 ± 69	1063 ± 94	
Alanine (μmol/l)						
Day 1	469 ± 54	407 ± 26	420 ± 421	377 ± 46	403 ± 33	0.342
Day 2	291 ± 34	311 ± 26	310 ± 31	257 ± 27	259 ± 26	

Data are means ± SE. *To convert growth hormone to pmol/l, multiply by 44.15; †to convert cortisol to nmol/l, multiply by 27.59.

FIG. 3. Mean ± SE values for neurogenic (*A*) and neuroglycopenic (*B*) symptom scores before and during hyperinsulinemic stepped hypoglycemic clamps before (day 1, ■) and after (day 2, □) ~24 h of hypoglycemia (55 mg/dl, 3.0 mmol/l) in nine subjects who underwent PET studies after hypoglycemia.

bility is <5% that blood-to-brain glucose transport was increased ≥20%, cerebral glucose metabolism was increased by ≥10%, or cerebral blood flow was increased by ≥16% after hypoglycemia.

DISCUSSION

These data do not support the hypothesis that recent antecedent hypoglycemia causes increased blood-to-brain glucose transport (17–22). Rates of blood-to-brain glucose transport, as well as those of cerebral glucose metabolism and cerebral blood flow (determined with radiotracers and PET) were virtually identical in healthy subjects studied after euglycemia and in those studied after ~24 h of interprandial hypoglycemia (~55 mg/dl, ~3.0 mmol/l). The mean plasma glucose level, including excursions after lunch, dinner, and a bed time snack, was 64 ± 1 mg/dl (3.6 ± 0.1 mmol/l). Although we cannot categorically exclude small differences (given our sample size), there was no trend in blood-to-brain glucose transport, cerebral glucose metabolism, or cerebral blood flow in the direction of our hypothesis. Indeed, the means of all three

FIG. 4. Mean ± SE values for plasma glucagon and pancreatic polypeptide concentrations before and during hyperinsulinemic stepped hypoglycemic clamps before (day 1, ■) and after (day 2, □) ~24 h of hypoglycemia (55 mg/dl, 3.0 mmol/l) in nine subjects who underwent PET studies after hypoglycemia.

TABLE 2
Neuroendocrine parameters during the PET studies in eight subjects studied after euglycemia and nine subjects studied after approximately 24 h of hypoglycemia*

	After EU	After HYPO	*P*
Glucose (mg/dl)	64 ± 0	66 ± 1	—
Epinephrine (pg/ml)	302 ± 77	112 ± 34	0.032
Norepinephrine (pg/ml)	253 ± 29	208 ± 31	0.310
Glucagon (pg/ml)	118 ± 29	43 ± 8	0.012
Pancreatic polypeptide (pg/ml)	117 ± 35	38 ± 9	0.035
Growth hormone (ng/ml)	12.1 ± 4.8	10.6 ± 4.1	0.809
Cortisol (μg/dl)	14.2 ± 2.4	11.7 ± 2.1	0.430

Data are means ± SE. *To convert glucose to mmol/l multiply by 0.0551, epinephrine to pmol/l multiply by 5.485, norepinephrine to nmol/l multiply by 0.005911, glucagon to pmol/l multiply by 0.2871, pancreatic polypeptide to pmol/l multiply by 0.239, growth hormone to pmol/l multiply by 44.15, and cortisol to nmol/l multiply by 27.59. EU, euglycemia; HYPO, hypoglycemia.

variables tended to be lower after hypoglycemia. Analysis of the differences between the groups disclosed that there is a <5% statistical probability that after hypoglycemia, blood-to-brain glucose transport was increased by 20%, which is the increase Boyle et al. (21) estimated was required in order to explain their findings. Similarly, there is a <5% probability that after hypoglycemia, cerebral blood flow was increased by 16%, which is approximately half the increase reported by Boyle et al. (21).

Because measurements of labeled glucose in brain were made shortly after intra-arterial injection of labeled glucose, the data indicating that 3–5 (17–19) or 14 (20) days of hypoglycemia increases brain glucose uptake in rodents largely reflect an increase in unidirectional blood-to-brain glucose transport. On the other hand, because the Kety-Schmidt technique measures net glucose uptake by the brain, the data indicating that 56 h of interprandial hypoglycemia (21) or frequent iatrogenic hypoglycemia in type 1 diabetes (22) increases brain glucose uptake during hypoglycemia largely reflect an increase in brain glucose metabolism. We measured blood-to-brain glucose transport and cerebral glucose metabolism in human subjects


FIG. 5. Mean ± SE rates of blood-to-brain glucose transport (*A*), cerebral glucose metabolism (*B*), and cerebral blood flow (*C*) determined with PET during hyperinsulinemic mildly hypoglycemic clamps (65 mg/dl, 3.6 mmol/l) in eight subjects studied after euglycemia (After EU) and nine subjects studied after ~24 h of hypoglycemia (55 mg/dl, 3.0 mmol/l) (After HYPO).

with a different method: [1-^{11}C]glucose and PET (23). This method has been validated in macaques, in which blood-to-brain glucose transport was shown to be related to arterial plasma glucose extraction by appropriate Michaelis-Menten kinetics, and net glucose extraction measured with the PET method correlated with that determined by arteriovenous glucose differences (23). It has also been applied to an earlier study in humans showing that neither blood-to-brain glucose transport nor cerebral glucose metabolism is reduced in poorly controlled type 1 diabetes (24). It differs from other PET methods (42–44) in that it uses both [^{11}C]glucose labeled in the C-1 position and a model that includes a fourth rate constant to account for the egress of [^{11}C]metabolites (23). We have determined that the calculated rates of blood-to-brain glucose transport and cerebral glucose metabolism determined with this method are unaffected by circulating radiolabeled nonglucose metabolites (40) and that blood-to-brain glucose transport varies as a function of the plasma glucose concentration (23,41).

In the subjects who underwent PET studies after hypoglycemia, glycemic thresholds for autonomic, symptomatic, and other responses to hypoglycemia were shifted to lower plasma glucose concentrations (i.e., lower plasma glucose levels were required to elicit these responses) after interval hypoglycemia, as expected (10–14,45,46). During hyperinsulinemic stepped hypoglycemic clamps, plasma epinephrine, neurogenic symptom scores, and plasma glucagon responses were reduced significantly, and plasma norepinephrine, neuroglycopenic symptom scores, and pancreatic polypeptide responses tended to be reduced after ~24 h of interprandial hypoglycemia. These are fundamental features of the concept of hypoglycemia-associated autonomic failure in type 1 diabetes (10–14) that we sought to explain mechanistically. If these threshold shifts were the result of increased blood-to-brain glucose transport, and thus of the provision of more glucose to the brain with correspondingly reduced responses during subsequent hypoglycemia, rates of blood-to-brain glucose transport should have been higher in these subjects than in those studied in the absence of antecedent hypoglycemia. However, that was not the case.

In the studies of Boyle et al. (21,22), using the Kety-Schmidt technique, the higher calculated rates of brain glucose uptake during hypoglycemia after 56 h of interprandial hypoglycemia in healthy subjects (21) and in patients with type 1 diabetes and HbA$_{1c}$ values in the lowest tertile (22) were a function of both higher rates of cerebral blood flow and larger glucose arteriovenous differences across the brain. Cerebral blood flow, measured with the nitrous oxide method, was higher after interprandial hypoglycemia at clamped plasma glucose concentrations as high as 65 mg/dl (3.6 mmol/l) in the former study (21). Indeed, in that study at the 65 mg/dl plasma glucose step, the calculated ~40% higher rate of brain glucose uptake was entirely attributable to an ~40% higher cerebral blood flow because the glucose arteriovenous difference was not higher. At the 55 mg/dl (3.0 mmol/l) glucose step, cerebral blood flow was ~30–35% higher, whereas the glucose arteriovenous difference was only ~5–10% higher. In contrast, with regard to the rates of cerebral blood flow (measured with [^{15}O]water and PET)

after ~24 h of hypoglycemia, we found no difference compared with the rates after euglycemia.

In theory, a difference in blood-to-brain glucose transport under these two study conditions would be demonstrable at any plasma glucose concentration, provided the glucose levels were comparable at the time of the measurements. However, we elected to perform the PET measurements at the mildly hypoglycemic level of 65 mg/dl (3.6 mmol/l). That approximates the plasma glucose concentration at which brain glucose uptake has been reported to begin to decline (21) and is slightly below the normal glycemic thresholds for glucose counterregulatory hormone secretion of ~65–68 mg/dl (3.6–3.8 mmol/l) (2,25,47,48). Notably, for plasma epinephrine, pancreatic polypeptide, and glucagon concentrations during this mild hypoglycemia at the time of the PET measurements in the subjects studied after interval hypoglycemia, levels were lower than in the subjects studied after euglycemia, providing additional evidence of the phenomenon we sought to explain mechanistically. Nonetheless, we found no effect of antecedent hypoglycemia on blood-to-brain glucose transport (or on cerebral glucose metabolism or cerebral blood flow) under this clinically relevant condition.

We studied the effect of only ~24 h of antecedent interprandial hypoglycemia and raised plasma glucose levels transiently to 85 mg/dl (4.7 mmol/l) (to repeat the hyperinsulinemic stepped hypoglycemic clamps) the morning before performing the PET studies on day 2 in the subjects studied after hypoglycemia. Thus, the duration of antecedent hypoglycemia was shorter than that in the earlier rodent studies (17–20) and one of the earlier human studies (21), and unlike the rodent studies (17–20), glucose levels were raised before the PET studies. However, even if our findings were different after a longer period of antecedent hypoglycemia, and even if plasma glucose levels were not raised temporarily before the PET studies, those findings would not be relevant to the clinical phenomenon we sought to explain mechanistically, i.e., elevated glycemic thresholds for autonomic (including epinephrine) and symptomatic responses after relatively brief episodes of iatrogenic hypoglycemia in people with diabetes.

The subjects studied after euglycemia, unlike those studied after hypoglycemia, were not subjected to hyperinsulinemia the previous day. However, antecedent hyperinsulinemic euglycemia, in contrast to hypoglycemia, does not reduce responses to hypoglycemia the following day (2,45). This is the phenomenon that we sought to explain mechanistically and that we documented in the present study. Furthermore, all of the PET studies were performed under hyperinsulinemic conditions. However, hyperinsulinemia per se does not increase blood-to-brain glucose metabolism or cerebral glucose metabolism (49,50).

Our data do not support the hypothesis that recent antecedent hypoglycemia causes increased global blood-to-brain glucose transport, but they do not exclude regional increments in blood-to-brain glucose transport. However, the published data in rodents (17–20) and humans (21,22) that provided the basis of the hypothesis we tested included measures of global, rather than regional, brain glucose transport and metabolism, respectively. Nonetheless, it is conceivable that regional increments in blood-to-brain glucose transport (e.g., in the ventromedial

hypothalamus, among other sites) might explain the phenomenon of hypoglycemia-associated autonomic failure in diabetes. Alternatively, the fundamental alteration might lie beyond the blood-brain barrier (51,52).

ACKNOWLEDGMENTS

REFERENCES

1. Cryer PE: Banting Lecture 1994: Hypoglycemia: the limiting factor in the management of IDDM. *Diabetes* 43:1378–1389, 1994
2. Cryer PE: *Hypoglycemia*: *Pathophysiology, Diagnosis and Treatment*. New York, Oxford University Press, 1997, p. 85–125
3. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329:977–986, 1993
4. The United Kingdom Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet* 352:837–853, 1998
5. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH: Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. *Science* 182:171–173, 1973
6. Bolli G, de Feo P, Compagnucci P, Cartechini MG, Angeletti F, Santeusanio F, Brunetti P, Gerich JE: Abnormal glucose counterregulation in insulin dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. *Diabetes* 32:134–141, 1983
7. White NH, Skor D, Cryer PE, Bier DM, Levandoski L, Santiago JV: Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. *N Engl J Med* 308:485–491, 1983
8. Bolli GB, De Feo P, De Cosmo S, Perriello G, Ventura MM, Benedetti MM, Santeusanio F, Gerich JE, Brunetti P: A reliable and reproducible test for adequate glucose counterregulation in type 1 diabetes. *Diabetes* 33:732–737, 1984
9. Gold AE, MacLeod KM, Frier BM: Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. *Diabetes Care* 17:697–703, 1994
10. Cryer PE: Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: a vicious cycle. *Diabetes* 41:255–260, 1992
11. Dagogo-Jack SE, Craft S, Cryer PE: Hypoglycemia-associated autonomic failure in insulin dependent diabetes mellitus. *J Clin Invest* 91:819–828, 1993
12. Ovalle F, Fanelli CG, Paramore DS, Hershey T, Craft S, Cryer PE: Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. *Diabetes* 47:1472–1479, 1998
13. Fanelli CG, Paramore DS, Hershey T, Terkamp C, Ovalle F, Craft S, Cryer PE: Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes mellitus. *Diabetes* 47:1920–1927, 1998
14. Dagogo-Jack S, Rattarasarn C, Cryer PE: Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. *Diabetes* 43:1426–1434, 1994
15. Fanelli CG, Pampanelli S, Epifano L, Rambotti AM, Vincenzo AD, Modarelli F, Ciofetta M, Lepore M, Annibale B, Torlone E, Perriello G, De Feo P, Santeusanio F, Brunetti P, Bolli GB: Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia following institution of rational intensive therapy in IDDM. *Diabetologia* 37:1265–1276, 1994
16. Cranston I, Lomas J, Maran A, Macdonald I, Amiel S: Restoration of hypoglycemia unawareness in patients with long duration insulin-dependent diabetes mellitus. *Lancet* 344:283–287, 1994
17. McCall AL, Fixman LB, Fleming N, Tornheim K, Chick W, Ruderman NB: Chronic hypoglycemia increases brain glucose transport. *Am J Physiol* 251:E442–E447, 1986
18. Koranyi L, Bourey RE, James D, Mueckler M, Fiedorek FT Jr, Permutt MA: Glucose transporter gene expression in rat brain: pre-translational changes associated with chronic insulin-induced hypoglycemia, fasting and diabetes. *Mol Cell Neurosci* 2:244–252, 1991
19. Kumagai AK, Kang YS, Boado RJ, Partridge WM: Upregulation of blood-brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. *Diabetes* 44:1399–1404, 1995
20. Simpson IA, Appel NM, Hokari M, Oki J, Holman GD, Maher F, Koehler-Stec EM, Vannnucci SJ, Smith QR: Blood-barrier glucose transporter: Effects of hypo- and hyperglycemia revisited. *J Neurochem* 72:238–247, 1999
21. Boyle PJ, Nagy RJ, O'Connor AM, Kempers SF, Yeo RA, Qualls C: Adaptation in brain glucose uptake following recurrent hypoglycemia. *Proc Natl Acad Sci U S A* 91:9352–9356, 1994
22. Boyle PJ, Kempers SF, O'Connor AM, Nagy RJ: Brain glucose uptake and unawareness of hypoglycemia in patients with insulin dependent diabetes mellitus. *N Engl J Med* 333:1726–1731, 1995
23. Powers WJ, Dagogo-Jack S, Markham J, Larsen KB, Dence CS: Cerebral transport and metabolism of 1-^{11}C-D-glucose during stepped hypoglycemia. *Ann Neurol* 38:599–609, 1995
24. Fanelli CG, Dence CS, Markham J, Videen T, Paramore DS, Cryer PE, Powers WJ: Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes. *Diabetes* 47:1444–1450, 1998
25. Schwartz NS, Clutter WE, Shah SD, Cryer PE: The glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. *J Clin Invest* 79:777–781, 1987
26. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH: Determination of free and total insulin and C-peptide in insulin-treated diabetics. *Diabetes* 26:22–29, 1977
27. Ensinck J: Immunoassays for glucagon. In *Handbook of Experimental Pharmacology*. Vol. 66. Lefebrve P, Ed. New York, Springer Verlag, 1983, p. 203–221
28. Gingerich RL, Lacy PE, Chance RE, Johnson MG: Regional pancreatic concentration and in-vitro secretion of canine pancreatic polypeptide, insulin, and glucagon. *Diabetes* 27:96–101, 1978
29. Schalch D, Parker M: A sensitive double antibody radioimmunoassay for growth hormone in plasma. *Nature* (*Lond*) 703:1141–1142, 1964
30. Farmer RW, Pierce CE: Plasma cortisol determination: radioimmunoassay and competitive protein binding compared. *Clin Chem* 20:411–414, 1974
31. Shah SD, Clutter WE, Cryer PE: External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. *J Lab Clin Med* 106:624–629, 1985
32. Hosaka K, Kikuchi T, Mitsuhida N, Kawaguchi A: A new colorimetric method for the determination of free fatty acids with acyl-CoA synthetase and acyl-CoA oxidase. *J Biochem* (*Tokyo*) 89:1799–1803, 1981
33. Pinter J, Hayaski J, Watson J: Enzymatic assay of glycerol, dihydroxyacetone and glyceraldehyde. *Arch Biochem Biophy* 121:404–414, 1967
34. Lowry O, Passoneau J, Hasselberger F, Schultz D: Effect of ischemia on known substrates and co-factors of the glycolyptic pathway of the brain. *J Biol Chem* 239:18–30, 1964
35. Cahill GF Jr, Herrera MG, Morgan AP, Soeldner JS, Steinke J, Levy PL, Reichard GA Jr, Kipnis DM: Hormone-fuel interrelationships during fasting. *J Clin Invest* 45:1751–1769, 1966
36. Towler DA, Havlin CE, Craft S, Cryer P: Mechanisms of awareness of hypoglycemia: perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. *Diabetes* 42:1791–1798, 1993
37. Videen TO, Perlmutter JS, Herscovitch P, Raichle ME: Brain blood volume, blood flow, and oxygen utilization measured with 0–15 radiotracers and positron emission tomography: revised metabolic computations. *J Cereb Blood Flow Metab* 7:513–516, 1987
38. Martin WRW, Powers WJ, Raichle ME: Cerebral blood volume measured with inhaled C[15]O and positron emission tomography. *J Cereb Blood Flow Metab* 7:421–426, 1987
39. Raichle ME, Martin WRW, Herscovitch P, Mintun MA, Markham J: Brain blood flow measured with intravenous $H_2^{15}O$. II. Implementation and validation. *J Nucl Med* 24:790–798, 1983
40. Powers WJ, Dence CS, Markham J, Videen TO, Segel S, Cryer PE: Effect of correction for labeled arterial metabolites on PET cerebral metabolism measurements with 11C-D-glucose during hyperinsulinemic clamps (Abstract). *J Nucl Med* 41:62P, 2000
41. Powers WJ, Rosenbaum JL, Dence CS, Markham J, Videen TO: Cerebral

glucose transport and metabolism in preterm human infants. *J Cereb Blood Flow Metab* 18:632–638, 1998

42. Brooks DJ, Gibbs JSR, Sharp P, Herold S, Turton DR, Luthra SK, Kohner EM, Bloom SR, Jones T: Regional cerebral glucose transport in insulin dependent diabetic patients studied using [^{11}C]3–0-methyl-D-glucose and positron emission tomography. *J Cereb Blood Flow Metab* 6:240–244, 1986

43. Eastman RC, Carson RE, Gordon MR, Berg GW, Lillioja S, Larson SM, Roth J: Brain glucose metabolism in non-insulin dependent diabetes mellitus: a study in Pima Indians using positron emission tomography during hyperinsulinemia with euglycemic clamp. *J Clin Endocrinol Metab* 71:1602–1610, 1990

44. Gutniak M, Blomqvist G, Widén L, Stone-Elander S, Hamberger B, Grill V: D-[U-^{11}C]glucose uptake and metabolism in the brain of insulin-dependent diabetic subjects. *Am J Physiol* 258:E805–E812, 1990

45. Heller SR, Cryer PE: Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. *Diabetes* 40:223–226, 1991

46. Davis MR, Shamoon H: Counterregulatory adaptation to recurrent hypoglycemia in normal humans. *J Clin Endocrinol Metab* 73:995–1001, 1991

47. Mitrakou A, Ryan C, Veneman T, Mokan M, Jensen T, Kiss I, Durant J, Cryer P, Gerich J: Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms and cerebral dysfunction. *Am J Physiol* 260:E67–E74, 1991

48. Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Ciofetta M, Modarelli F, Vincenzo AD, Annibale B, Lepore M, Lalli C, Del Sindaco P, Brunetti P, Bolli GB: Relative roles of insulin and hypoglycemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycemia in male and female humans. *Diabetologia* 37:797–807, 1994

49. Knudsen GM, Hasselbalch SG, Hertz MM, Paulson OB: High dose insulin does not increase glucose transfer across the blood-brain barrier in humans: a re-evaluation. *Eur J Clin Invest* 29:687–691, 1999

50. Cranston I, Marsden P, Matyka K, Evans M, Lomas J, Sönksen P, Maisey M, Amiel SA: Regional differences in cerebral blood flow and glucose utilization in diabetic man: the effect of insulin. *J Cereb Blood Flow Metab* 18:130–140, 1998

51. Borg MA, Borg WP, Tamborlane WV, Brines ML, Shulman GI, Sherwin RS: Chronic hypoglycemia and diabetes impair counterregulation induced by localized 2-deoxyglucose perfusion of the ventromedial hypothalamus in rats. *Diabetes* 48:584–587, 1999

52. Jacob RJ, Fan X, Zhu Y, McCrimmon RJ, Sherwin RS: Does antecedent recurrent hypoglycemia alter brain ECF glucose levels during acute hypoglycemia in diabetes? (Abstract). *Diabetes* 48:A56, 1999